UK-based CRO Charnwood Molecular reveals plans for ‘significant’ expansion in 2021 29th April 2021 Charnwood Molecular recently announced a partnership with private equity fund Synoya to further its expansion plans. This deal, according to the CRO, provided additional capital to support the company’s future development and growth, including hiring additional senior leadership team members. The expansion plans include Charnwood Molecular becoming the sole occupier of a ‘state-of-the-art’ laboratory facility at Charnwood Campus, based in Loughborough. This campus was recently designated a ‘Life Sciences Opportunity Zone’, Charnwood Molecular said in a statement, allowing for greater collaboration and accelerated business growth within the med-tech and biopharma industries.